Marshall Beth C, Adler Stuart P
Department of Pediatrics, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia 23298, USA.
Viral Immunol. 2003;16(4):491-500. doi: 10.1089/088282403771926319.
Two human cytomegalovirus (CMV) vaccines have been previously evaluated for their immunogenicity: a recombinant gB/MF59 vaccine and an attenuated strain of CMV (Towne). In healthy adults, we measured the antibody avidity maturation indices that occurred after vaccination with each. For Towne, administered as a single dose, the rise in IgG antibody avidity to CMV glycoprotein gB occurred slowly and continued for 24 months post-immunization. For gB/MF59, administered as two priming doses and a booster dose given at 6 months, the booster rapidly induced IgG antibodies to gB whose avidity was maximal at 7 months after the initial priming dose. Both vaccines induced antibody levels and avidity maturation indices that equaled those induced by wild-type virus suggesting that both vaccines may be effective in controlling CMV infections.
此前已对两种人巨细胞病毒（CMV）疫苗的免疫原性进行了评估：一种重组gB/MF59疫苗和一种CMV减毒株（汤氏株）。在健康成年人中，我们测量了接种每种疫苗后出现的抗体亲和力成熟指数。对于单次接种的汤氏株疫苗，接种后针对CMV糖蛋白gB的IgG抗体亲和力上升缓慢，并在免疫后持续24个月。对于gB/MF59疫苗，按两次初免剂量和6个月后一次加强剂量接种，加强剂量迅速诱导出针对gB的IgG抗体，其亲和力在初次接种剂量后7个月时达到最大值。两种疫苗诱导的抗体水平和亲和力成熟指数均与野生型病毒诱导的相当，这表明两种疫苗在控制CMV感染方面可能都有效。
